» Home / Life Sciences Financing Goes Global, Possibly to the Detriment of U.S. Companies

Life Sciences Financing Goes Global, Possibly to the Detriment of U.S. Companies

January 13, 2011

Uncertainty around health care reform and FDA regulations may be hindering global financing for U.S companies in fields such as biotechnology, pharmaceuticals and biomedical technologies.

By Udayan Gupta

Life sciences companies in fields such as biotechnology, pharmaceuticals and biomedical technologies had a banner financing year in 2010, in spite of the fact that the health care sector was among the worst performing sectors in the stock market.

Not registered with Institutional Investor?

Subscribe

Start your subscription today for unrestricted access.

Subscribe Now

Free Trial

Register today for a free 2-week trial.

Free Trial

Login

Already have an account?

Please sign in below:

Forgot Password?

Related Articles